



Substitute form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	10/517,264
Filing Date	September 30, 2005
First Named Inventor	Eric Francis Morand, et al.
Art Unit	1626
Examiner Name	Susannah Lee Chung
Attorney Docket Number	11982.105001 (BDW003)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	MORAND, et al.; "Macrophage Migration Inhibitory Factor"; <u>Arthritis &amp; Rheumatism</u> , Vol. 48, No. 2, February, 2003, pp. 2910-299	
	AB	DE JONG, et al.; "Development of chronic colitis is dependent on the cytokine MIF"; <u>Nature Immunology</u> , November, 2001, Vol. 2 No. 11; pp. 1061-1066	
	AC	YU, et al.; "Expression of Macrophage Migration Inhibitory Factor In Acute Ischemic Myocardial Injury"; <u>The Journal of Histochemistry &amp; Cytochemistry</u> , Volume 51(5):625-631, 2003	
	AD	KOBAYASHI, et al.; "Prevention of Lethal Acute Hepatic Failure by Antimacrophage Migration Inhibitory Factor Antibody in Mice Treated With Bacille Calmette-Guerin and Lipopolysaccharide"; <u>Hepatology</u> , Vol. 29, No. 6, 1999, pp. 1752-1759	
	AE	HE, et al.; "Macrophage Migration Inhibitory Factor Promotes Colorectal Cancer"; <u>Mol. Med.</u> 15(1-2) 1-10, January-February, 2009	
	AF	CALANDRA, et al.; "Protection from septic shock by neutralization of macrophage migration inhibitory factor"; <u>Nature Medicine</u> , Vol. 6, Number 2, February, 2000, pp. 164-170	
	AG	PAN, et al.; "Macrophage Migration Inhibitory Factor Deficiency Impairs Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice"; <u>Circulation Journal of the American Heart Association</u> , March 18, 2009; pp. 3149-3153	
	AH	STOSIC-GRUJICIC, et al.; "Macrophage Migration Inhibitory Factor (MIF) Is Necessary for Progression of Autoimmune Diabetes Mellitus"; <u>Journal of Cellular Physiology</u> ; pp. 665-675	
	AI	SANCHEZ, et al.; "Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus"; <u>Genes and Immunity</u> (2006), 1-4	
	AJ	MAGALHAES, et al.; "Macrophage migration inhibitory factor is essential for allergic asthma but not for Th2 differentiation"; <u>European Journal of Immunology</u> , 2007, 37: 1097-1106	
	AK	CHESNEY, et al.; "An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma"; <u>Molecular Medicine</u> 5: 181-191, 1999	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

Application Number	10/517,264
Filing Date	September 30, 2005
First Named Inventor	Eric Francis Morand, et al.
Art Unit	1626
Examiner Name	Susannah Lee Chung
Attorney Docket Number	11982.105001 (BDW003)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BA	SHIMIZU, et al.; "High Macrophage Migration Inhibitory Factor (MIF) Serum Levels Associated with Extended Psoriasis"; <u>The Society for Investigative Dermatology, Inc.</u> , pp. 989-990	
	BB	DENKINGER, et al., "In Vivo Blockade of Macrophage Migration Inhibitory Factor Ameliorates Actue Experimental Autoimmune Encephalomyelitis by Impairing the Homing of Encephalitogenic T Cells to the Central Nervous System"; <u>The Journal of Immunology</u> ; pp. 1274-1282	
	BC	MEYER-SIEGLER, et al.; "Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer"; <u>BMC Cancer</u> 2005, 5:73; pp. 1-12	
	BD	ONODERA, et al.; "Transgenic Mice Overexpressing Macrophage Migration Inhibitory Factor (MIF) Exhibit High-Turnover Osteoporosis"; <u>Journal of Bone and Mineral Research</u> ; Vol. 21, Number 6, 2006, pp. 876-885	
	BE	LAN, et al.; "The Pathogenic Role of Macrophage Migration Inhibitory Factor in Immunologically Induced Kidney Disease in the Rat"; <u>J. Exp. Med.</u> , Volume 185, Number 8, April 21, 1997, pp. 1455-1465	
	BF	HARDMAN, et al.; "Macrophage Migration Inhibitory Factor, A Central Regulator of Wound Healing"; <u>American Journal of Pathology</u> , Vol. 167, No. 6, December 2005, pp. 1561-1574	
	BG	MARTIN, et al.; "Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB)-induced nonmelanoma skin cancer (NMSC)"; <u>The FASEB Journal</u> , Vol. 23, March 2009, pp. 720-730	
	BH	RENDON, et al.; "Regulation of Human Lung Adenocarcinoma Cell Migration and Invasion by Macrophage Migration Inhibitory Factor"; <u>Journal of Biological Chemistry</u> , Volume 282, Number 41, October 12, 2007, pp. 29910-29918	
	BI	SHIMIZU, et al.; "High Expression of Macrophage Migration Inhibitory Factor in Human Melanoma Cells and Its Role in Tumor Cell Growth and Angiogenesis"; <u>Biochemical and Biophysical Research Communications</u> 264, 751-758 (1999)	
	BJ	SHUN, et al.; "Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas"; <u>World Journal of Gastroenterology</u> 2005; 11(24)-3767-3771	
	BK	REN, et al.; "Macrophage Migration Inhibitory Factor: Roles in Regulating Tumor Cell Migration and Expression of Angiogenic Factors in Hepatocellular Carcinoma"; <u>Int. J. Cancer</u> ; 107, 22-29 (2003)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 3

**Complete if Known**

Application Number	10/517,264
Filing Date	September 30, 2005
First Named Inventor	Eric Francis Morand, et al.
Art Unit	1626
Examiner Name	Susannah Lee Chung
Attorney Docket Number	11982.105001 (BDW003)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	NUNEZ, et al.; "Involvement of macrophage migration inhibitory factor gene in celiac disease susceptibility"; <u>Genes and Immunity</u> (2007) 8, 168-170	
	CB	XU, et al.; "Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer"; <u>Cancer Letters</u> 261 (2008) 147-157	
	CC	SELVI, et al.; "Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis"; <u>Ann Rheum Dis</u> 2003; 62:460-464	
	CD	BERDELI, et al.; "Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome"; <u>Pediatr Nephrol</u> (2005) 20:1566-1571	
	CE	DE BENEDETTI, et al.; "Functional and Prognostic Relevance of the -173 Polymorphism of the Macrophage Migration Inhibitory Factor Gene in Systemic-Onset Juvenile Idiopathic Arthritis"; <u>Arthritis &amp; Rheumatism</u> , Vol. 48, No. 5, May 2003, pp. 1398-1407	
	CF	KOTAKE, et al.; "Macrophage Migration Inhibitory Factor in Uveitis"; pp. 99-103	
	CG	TASHIMO, et al.; "Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy"; 2004 <u>Diabetic Medicine</u> , 21, 1292-1297	
	CH	HAGEMANN, et al.; "Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis"; <u>Mol Cancer Ther</u> 2007;6(7), July 2007	
	CI	MEYER-SIEGLER, et al.; "Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells"; <u>BMC Cancer</u> 2004, 4:34, pp. 1-12	
	CJ	NAKAMAUR, et al.; "Prognostic significance of cytoplasmic macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy"; <u>Oncol Rep</u> , 2005 Jan;13(1):59-64	
	CK	REN, et al.; "Macrophage Migration Inhibitory Factor Stimulates Angiogenic Factor Expression and Correlates With Differentiation and Lymph Node Status in Patients With Esophageal Squamous Cell Carcinoma"; <u>Annals of Surgery</u> , Volume 242, Number 1, July 2005, pp. 55-63	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/517,264

Filing Date

September 30, 2005

First Named Inventor

Eric Francis Morand, et al.

Art Unit

1626

Examiner Name

Susannah Lee Chung

Attorney Docket Number

11982.105001 (BDW003)

## ENCLOSURES (check all that apply)

☒ Fee Transmittal Form

☒ Fee Attached

☒ Amendment / Reply

☐ After Final

☐ Affidavits/declaration(s)

☒ Extension of Time Request

☐ Express Abandonment Request

☒ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Reply to Missing Parts/  
Incomplete Application

☐ Reply to Missing Parts  
under 37 CFR 1.52 or 1.53

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a  
Provisional Application

☐ Power of Attorney, Revocation  
Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CD

☐ After Allowance Communication to TC

☐ Appeal Communication to Board  
of Appeals and Interferences

☐ Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s)  
(please identify below):

References (33)

Postcard

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

King & Spalding LLP

Signature

Printed Name

Stephen C. MacDonald, Ph.D.

Date

March 20, 2009

Reg. No.

60,401

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name

Stephen C. MacDonald, Ph.D.

Date

March 20, 2009

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.